
	Chemical structure search How to Search	Import MOLfile format is only available (V3000 format is not available) Exact match Substructure search Superstructure search Substructure or superstructure search Similarity search

Details
Related links
Search

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr

J-GLOBAL ID：201101025890663213 Update date: Apr. 09, 2025

HIROAKI OZASA

オザサヒロアキ | HIROAKI OZASA

Clips

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (7)：

2024 - 2027 一塩基多型を用いた免疫チェックポイント阻害薬の新規バイオマーカーの探索
2023 - 2026 肺癌転移性肝腫瘍における肝転移生体内観察モデルを用いた新規治療戦略の開発
2020 - 2023 肺癌転移性脳腫瘍の生体内観察モデルを用いた、新規治療薬の検討
2021 - 2023 脳内微小環境と癌細胞の相互作用を解明する異分野融合的解析法
2019 - 2022 Development of new therapeutic strategies for driver mutation-positive lung cancer

Show all

Papers (79)：

Yusuke Shima, Hironori Yoshida, Keiichiro Suminaga, Hiroshi Yoshida, Kentaro Hashimoto, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Funazo, Takashi Nomizo, et al. Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study. BMC Cancer. 2025. 25. 1
Keiichiro Suminaga, Takashi Nomizo, Hironori Yoshida, Hiroaki Ozasa. The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study. Journal of Cancer Research and Clinical Oncology. 2025. 151. 2
Masatsugu Hamaji, Hiroaki Ozasa, Yuichi Sakamori, Kazuhiro Terada, Akihiko Yoshizawa, Ryutaro Kikuchi, Yasuto Sakaguchi, Makoto Sonobe, Yusuke Muranishi, Ryo Miyahara, et al. Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer. Journal of thoracic disease. 2024. 16. 9. 6094-6100
Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivin, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol . 2024
Masahiro Yoneyama, Yukinori Matsuo, Noriko Kishi, Ryo Itotani, Tsuyoshi Oguma, Hiroaki Ozasa, Kiminobu Tanizawa, Tomohiro Handa, Toyohiro Hirai, Takashi Mizowaki. Quantitative analysis of interstitial lung abnormalities on computed tomography to predict symptomatic radiation pneumonitis after lung stereotactic body radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024. 198. 110408-110408

ｍore...

MISC (153)：

橋本健太郎, 小笹裕晃, 島佑介, 住永圭一郎, 吉田寛, 細谷和貴, 船造智子, 味水瞳, 吉田博徳, 野溝岳, et al. ALK肺がんにおける分子標的薬に対するTEAD阻害薬の併用効果のバイオマーカー探索(Biomarkers for Efficacy of TEAD Inhibitor Combination with Molecularly targeted drugs in ALK Lung Cancer). 日本癌学会総会記事. 2024. 83回. P-1227
吉田寛, 小笹裕晃, 味水瞳, 細谷和貴, 島佑介, 住永圭一郎, 橋本健太郎, 山本智子, 野溝岳, 吉田博徳, et al. 肺癌肝転移成立の機序からの新規治療因子の探索(Exploration of novel therapeutic factors in the mechanism of establishment of liver metastases in lung cancer). 日本癌学会総会記事. 2024. 83回. P-3089
細谷和貴, 小笹裕晃, 辻貴宏, 島佑介, 住永圭一郎, 橋本健太郎, 吉田寛, 味水瞳, 船造智子, 吉田博徳, et al. 新たな肺腺癌脳転移モデルを用いた抗PD-1/CTLA-4抗体併用療法の有効性と作用機序の検討(Novel Model of Lung Adenocarcinoma Brain Metastasis Reveals Efficacy of Anti-PD-1/CTLA-4 Combination Therapy). 日本癌学会総会記事. 2024. 83回. P-3090
横井茉里, 米澤淳, 平大樹, 半田知宏, 谷澤公伸, 中川俊作, 池見泰明, 糸谷涼, 吉田博徳, 野村基雄, et al. 免疫チェックポイント阻害薬による間質性肺疾患の自覚症状と重症度の関連. 日本臨床免疫学会総会プログラム・抄録集. 2023. 51回. 123-123
名取大輔, 橋本健太郎, 吉田寛, 味水瞳, 野溝岳, 吉田博徳, 小笹裕晃, 平井豊博, 吉岡正博, 金井雅史, et al. オンコマインでドライバー遺伝子検出されず,Foundation OneでSCL8A1-ALK融合遺伝子が検出され,アレクチニブが有効であったALK陽性肺腺癌の1例. 肺癌. 2023. 63. 6. 903-903

ｍore...

Books (3)：